MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Charles River Laboratories International Inc

Fermé

SecteurSoins de santé

219.06 0.06

Résumé

Variation du prix de l'action

24h

Actuel

Min

214.89

Max

227.8

Chiffres clés

By Trading Economics

Revenu

2.9M

56M

Ventes

-27M

1B

BPA

2.43

Marge bénéficiaire

5.529

Employés

18,700

EBITDA

-23M

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-6.22% downside

Dividendes

By Dow Jones

Prochains Résultats

18 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

1.5B

10B

Ouverture précédente

219

Clôture précédente

219.06

Sentiment de l'Actualité

By Acuity

50%

50%

173 / 370 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

12 janv. 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12 janv. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 janv. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12 janv. 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 janv. 2026, 23:18 UTC

Acquisitions, Fusions, Rachats

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 janv. 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 janv. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12 janv. 2026, 21:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

12 janv. 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12 janv. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 janv. 2026, 20:54 UTC

Résultats

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 janv. 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 janv. 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 janv. 2026, 20:18 UTC

Acquisitions, Fusions, Rachats

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 janv. 2026, 20:18 UTC

Acquisitions, Fusions, Rachats

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 janv. 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 janv. 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 janv. 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 janv. 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 janv. 2026, 19:24 UTC

Acquisitions, Fusions, Rachats

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 janv. 2026, 19:22 UTC

Acquisitions, Fusions, Rachats

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 janv. 2026, 18:21 UTC

Acquisitions, Fusions, Rachats

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 janv. 2026, 18:20 UTC

Acquisitions, Fusions, Rachats

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 janv. 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 janv. 2026, 18:16 UTC

Market Talk
Acquisitions, Fusions, Rachats

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 janv. 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 janv. 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 janv. 2026, 18:01 UTC

Acquisitions, Fusions, Rachats

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 janv. 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

-6.22% baisse

Prévisions sur 12 Mois

Moyen 202.1 USD  -6.22%

Haut 225 USD

Bas 170 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

12 ratings

8

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

173 / 370Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat